Retracted: The Importance of Early Intervention in Multiple Sclerosis

Chairperson:

Carrie M Hersh ¹

Speakers:

Eva Kubala Havrdová , ² Klarissa Hanja Stürner ³

1. Cleveland Clinic Lou Ruvo Center for Brain Health, Nevada, USA
2. Charles University, Prague, Czechia
3. Christian-Albrecht University of Kiel, Germany

Disclosure:

Hersh has received speaking, consulting and advisory board fees from Genentech, Genzyme, Biogen, Novartis, EMD-Serono, Bristol Myers Squibb, TG Therapeutics, Horizon Therapeutics, and Alexion; and research support paid to their institution has been received from Biogen, Novartis, Bristol Myers Squibb, Patient-Centered Outcomes Research Institute (PCORI), and National Institutes of Health (NIH). Havrdová has received honoraria/research support from Biogen, Merck Serono, Novartis, Roche, and Teva; speaking fees from Bristol Myers Squibb; served as a member of advisory boards for Actelion, Biogen, Celgene, Merck Serono, Novartis, and Sanofi Genzyme; has been supported by the Czech Ministry of Education and the National Institute for Neurological Research; and been funded by the European Union-Next Generation EU. Stürner has received personal fees from Merck KGaA, Roche Pharma AG, Bristol Myers Squibb, and Argenx.

Acknowledgements:

Medical writing assistance was provided by Samantha Coates, Reading, UK. Thanks are given to the presenters of the sessions summarised in this article.

Disclaimer:

Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.

Ozanimod® is subject to additional monitoring. This will allow quick identification of new safety information.

Prescribing information for HCPs in the UK can be found here.
Prescribing information for HCPs in Ireland can be found here.

Adverse events should be reported. Reporting forms and information can be found via: Great Britain & Northern Ireland – The Yellow Card Scheme at: www.mhra.gov.uk/yellowcardor search for MHRA Yellow Card in the Google Play or Apple App store; Ireland – HPRA Pharmacovigilance at www.hpra.ie

Adverse events should also be reported to Bristol-Myers Squibb via [email protected]or 08007311736 (Great Britain & Northern Ireland); 1 800 749 749 (Ireland).

Support:

The publication of this article was funded by Bristol Myers Squibb, who reviewed the content for medical accuracy. The views and opinions expressed are exclusively those of the speakers.

Citation:

EMJ Neurol. 2025;13[Suppl 2]:2-8. https://doi.org/10.33590/emjneurol/FTMZ5541.

Keywords:

Brain atrophy, DAYBREAK, disease-modifying therapy (DMT) safety, disease-modifying therapy (DMT) switch, multiple sclerosis (MS), ozanimod.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.